Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) gapped up prior to trading on Tuesday. The stock had previously closed at $13.95, but opened at $14.97. Bayer Aktiengesellschaft shares last traded at $14.95, with a volume of 160,871 shares trading hands.
Analysts Set New Price Targets
Separately, Zacks Research raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Friday, July 10th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy".
Check Out Our Latest Analysis on BAYRY
Bayer Aktiengesellschaft Stock Performance
The stock's 50 day moving average price is $13.43 and its 200 day moving average price is $12.55. The company has a current ratio of 1.04, a quick ratio of 0.67 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $58.75 billion, a price-to-earnings ratio of -29.31, a P/E/G ratio of 1.94 and a beta of 0.57.
Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported $0.11 earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by ($0.02). Bayer Aktiengesellschaft had a positive return on equity of 16.77% and a negative net margin of 3.80%. Analysts expect that Bayer Aktiengesellschaft will post 1.27 earnings per share for the current year.
About Bayer Aktiengesellschaft
(
Get Free Report)
Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.
Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women's health, oncology, hematology and specialty therapies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bayer Aktiengesellschaft, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bayer Aktiengesellschaft wasn't on the list.
While Bayer Aktiengesellschaft currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.